Allogene Therapeutics (ALLO) Equity Average (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Equity Average for 7 consecutive years, with $303.9 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 31.39% to $303.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $303.9 million through Dec 2025, down 31.39% year-over-year, with the annual reading at $357.4 million for FY2025, 23.51% down from the prior year.
- Equity Average hit $303.9 million in Q4 2025 for Allogene Therapeutics, down from $329.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $1.0 billion in Q2 2021 to a low of $303.9 million in Q4 2025.
- Historically, Equity Average has averaged $646.9 million across 5 years, with a median of $603.9 million in 2023.
- Biggest five-year swings in Equity Average: soared 68.61% in 2021 and later tumbled 32.58% in 2025.
- Year by year, Equity Average stood at $947.6 million in 2021, then dropped by 25.58% to $705.1 million in 2022, then fell by 22.51% to $546.4 million in 2023, then fell by 18.94% to $443.0 million in 2024, then plummeted by 31.39% to $303.9 million in 2025.
- Business Quant data shows Equity Average for ALLO at $303.9 million in Q4 2025, $329.9 million in Q3 2025, and $365.0 million in Q2 2025.